Paul Shami is an Oncology physician affiliated with University of Utah. OpenAlex indexes 170 publications with 6,968 citations (h-index 39); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1950 Circle Of Hope Dr
Salt Lake City, UT 841125500
Telephone
801-581-2121Provider last certified this registry record 8 Nov 2021.
Clinical trials
- Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Sponsor: National Cancer Institute (NCI)
- Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia
Sponsor: Jazz Pharmaceuticals
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Daiichi Sankyo Inc.Program year20221 payment
- E.R. Squibb & Sons, L.L.C.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
5 NIH research awards on record, funded 2000–2014 per NIH RePORTER. The latest:
- Preclinical Development of JS-K, a Novel NO-Generating Prodrug for Cancer
Jsk Therapeutics, Inc.
FY2014$142,814R44CA156812 - Preclinical Development of JS-K, a Novel NO-Generating Prodrug for Cancer
Jsk Therapeutics, Inc.
FY2012$927,566R44CA156812
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Menin Inhibition With Revumenib for <i>KMT2A</i> -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)
Journal of Clinical Oncology
2024 - Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2024 - Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Colman, MD
University of Utah
Michael Varner, MD
University of Utah
James Fang
University of Utah
Wallace Akerley, MD
University of Utah
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”